Vistagen Therapeutics Inc (VTGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 03-2016 | 03-2015 | 03-2014 | 03-2013 | 03-2012 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -47,221 | -13,886 | -2,968 | -12,887 | -12,210 |
| Depreciation Amortization | 591 | 3,417 | 695 | 289 | 1,022 |
| Accounts receivable | N/A | N/A | N/A | 106 | -64 |
| Other Working Capital | -522 | 2,132 | 2,305 | 1,624 | 615 |
| Other Operating Activity | 42,343 | 5,569 | -2,158 | 7,404 | 7,071 |
| Operating Cash Flow | $-4,809 | $-2,769 | $-2,126 | $-3,463 | $-3,566 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -26 | N/A | -10 | -135 | -32 |
| Investing Cash Flow | $-26 | $N/A | $-10 | $-135 | $-32 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | 250 | 3,222 | 467 |
| Debt Repayment | -113 | -308 | -156 | -514 | -772 |
| Common Stock Issued | 280 | 3,147 | 1,340 | 1,447 | 3,846 |
| Other Financing Activity | 5,026 | 0 | 64 | 0 | 0 |
| Financing Cash Flow | $5,193 | $2,839 | $1,498 | $4,156 | $3,540 |
| Beginning Cash Position | 70 | N/A | 638 | 81 | 139 |
| End Cash Position | 429 | 70 | N/A | 638 | 81 |
| Net Cash Flow | $359 | $70 | $-638 | $557 | $-58 |
| Free Cash Flow | |||||
| Operating Cash Flow | -4,809 | -2,769 | -2,126 | -3,463 | -3,566 |
| Capital Expenditure | -26 | N/A | -10 | -135 | -32 |
| Free Cash Flow | -4,835 | -2,769 | -2,136 | -3,599 | -3,598 |